mRNA vaccines (conventional and nucleoside-modified)

Technology class

mRNA vaccines (conventional and nucleoside-modified)

Methods and compositions for nucleoside-modified mRNA vaccines encoding viral antigens

mRNA vaccines encode viral antigens as synthetic messenger RNA that directs host cells to produce immunogenic proteins, enabling rapid sequence-to-candidate timelines measured in weeks rather than months. This platform underpins the first vaccines authorized against SARS-CoV-2 and represents the most clinically validated nucleic acid approach, with billions of doses administered globally since 2020.

Route of administrationIntramuscular injection
Cold-chain needRefrigerated (2–8 °C)
Platform maturityLicensed product exists
Component roleComplete vaccine platform
Filing growth, 2014–23+26.4% a year
Top 4 holders hold32%
Patent holders145
Effective holders39
Commercial products176

Effective holders is the inverse of the HHI (1 ÷ HHI): a measure of how concentrated patent ownership is in this class.

Technology mechanism

Conventional mRNA vaccines deliver a linear, capped, polyadenylated transcript encoding the target antigen, typically a viral surface glycoprotein such as the SARS-CoV-2 spike or influenza hemagglutinin. Nucleoside modification—most commonly substitution of uridine with N1-methylpseudouridine—reduces innate immune sensing via Toll-like receptors and cytoplasmic RNA sensors, improving translational efficiency and tolerability while extending antigen expression duration from hours to approximately 24–72 hours post-injection. The mRNA construct includes optimized 5′ and 3′ untranslated regions selected for ribosome recruitment and transcript stability, codon optimization for human expression, and a poly(A) tail of 100–150 nucleotides. Manufacturing proceeds through enzymatic in vitro transcription using T7 RNA polymerase from a linearized DNA template, followed by capping (enzymatic or co-transcriptional), purification to remove double-stranded RNA contaminants that trigger interferon responses, and formulation into lipid nanoparticles (see M4) that protect the payload and facilitate endosomal escape. Typical antigen doses range from 25 to 100 micrograms of mRNA per injection for COVID-19 vaccines, with influenza candidates exploring doses as low as 10 micrograms per strain component. Unlike self-amplifying RNA (M2), conventional mRNA does not encode replicase machinery, resulting in a smaller transcript (approximately 4,000–5,000 nucleotides versus 9,000–12,000 for saRNA) but requiring higher mRNA mass to achieve comparable antigen output. The platform's modularity allows antigen sequence updates within days of variant identification, with clinical-grade material producible in six to eight weeks under established processes.

Operational footprint

Current authorized mRNA vaccines require frozen storage, with original formulations specified at minus 70 degrees Celsius and subsequent presentations stable at minus 20 degrees Celsius or refrigerated conditions for defined periods—typically two to four weeks at 2–8 degrees Celsius depending on product and presentation. Multi-dose vials (five or six doses) require dilution with saline before administration and must be used within defined windows after first puncture, generally six to twelve hours. These cold-chain and handling requirements have constrained deployment in settings lacking ultra-cold freezers or reliable refrigeration, though reformulation efforts continue to extend ambient and refrigerated stability. Administration is intramuscular, compatible with standard vaccination infrastructure and requiring no specialized injection devices. Manufacturing scale-up demands GMP-grade plasmid DNA supply, enzymatic reagents, and lipid nanoparticle production capacity; global fill-finish constraints became rate-limiting during pandemic response. Training requirements for vaccinators are minimal beyond standard injection technique, though pharmacy-level handling of frozen product and reconstitution protocols require specific procedural compliance.

Maturity signals

The platform achieved regulatory authorization faster than any prior vaccine technology, with emergency use authorizations granted in late 2020 followed by full biologics license approvals in August 2021 (Comirnaty) and January 2022 (Spikevax). Real-world effectiveness data from national immunization programs spanning hundreds of millions of recipients established efficacy against severe disease, hospitalization, and death across multiple SARS-CoV-2 variants. Moderna's mRNA influenza vaccine mFLUSIVA was approved by FDA in August 2026 for adults aged 50 and older, Moderna's flu/COVID-19 combination vaccine mCOMBRIAX (mRNA-1083) was authorized in the EU in April 2026 for adults aged 50 and older, and Moderna's mRNA RSV vaccine mRESVIA was licensed by FDA in May 2024; Moderna discontinued its congenital CMV program after a Phase 3 miss in October 2025. Patent activity is dense and concentrated, with ModernaTx and the University of Pennsylvania holding foundational intellectual property on nucleoside modification and lipid nanoparticle delivery, while CureVac, Sanofi, and BioNTech maintain substantial portfolios covering construct design, manufacturing processes, and specific antigen applications. The competitive landscape reflects both platform breadth and freedom-to-operate complexity, as multiple enabling technologies—mRNA architecture, LNP composition, antigen stabilization—intersect across assignees. White space exists in thermostable formulations, intranasal delivery of mRNA, and combination vaccines encoding multiple pathogen antigens.

Challenges

Cold-chain dependence remains the primary deployment barrier, limiting reach in tropical climates and resource-limited health systems where ultra-cold or even standard refrigeration is unreliable. Reactogenicity—including injection-site pain, fatigue, fever, and headache—is more pronounced than with protein subunit vaccines (M8) and may affect booster acceptance in some populations. Durability of immune responses has required booster doses at six- to twelve-month intervals for sustained protection against symptomatic infection, though protection against severe disease persists longer. Manufacturing complexity includes dependence on proprietary lipid components, enzymatic reagents with limited global suppliers, and stringent purification to remove immunostimulatory double-stranded RNA byproducts. Intellectual property entanglement across mRNA design, nucleoside chemistry, and LNP formulation creates licensing complexity for new entrants. Unlike live-attenuated vaccines (M12), mRNA does not induce mucosal immunity when delivered intramuscularly, limiting impact on viral transmission; intranasal mRNA delivery remains investigational with formulation challenges related to mucosal barriers and RNA stability.

← Back to what’s inside this report